Table 3.

Survival outcomes of second-line therapy.

Variable	N	mPFS2 (mo—IQ range)	P value	mOS2 (mo—IQ range)	P value
2LT
Platinum	21	8.8 (3.3–13.2)	0.013	13.5 (8.6–18.2)	0.82
No platinum	22	3.7 (1.8–9.1)		7.2 (3.0–27.4)
Germline BRCA pv			0.81		0.17
1	10	2.9 (2.0–9.0)		6.0 (5.3–13.5)
2	33	6.9 (2.7–10.2)		13.5 (6.3–25)
Gender			0.84		0.57
Male	20	7.4 (3.0–11.0)		14.1 (5.9–24.0)
Female	23	6.4 (2.1–10.2)		12.9 (5.3–25.0)
Age at 2LT start (years)			0.28		0.21
≤65	35	6.5 (2.7–10.3)		13.5 (6.0–25.0)
>65	8	3.4 (1.9–9.1)		9.3 (2.1–16.0)
Previous PFS1 (mo)			0.01		0.58
≤6	14	9.7 (2.5–16)		12.7 (7.2–28.0)
>6	29	4.3 (2.2–9.0)		12.9 (5.3–24.0)

mPFS₂ median progression-free survival 2, mOS₂ median overall survival 2, mo months, IQ interquartile, 2LT second-line therapy, pv pathogenic variant, PFS₁ progression-free survival 1.

Statistically significant p-values are in bold.